Design of novel tazarotene derivatives as potential antipsoriatic drugs: physicochemical properties study and molecular docking analysis of their binding to retinoic acid receptor family (RAR-alpha, RAR-beta and RAR-gamma)
Journal: Journal of Medicinal and Chemical Sciences (Vol.3, No. 2)Publication Date: 2020-04-01
Authors : Mehdi Nabati; Vida Bodaghi-Namileh;
Page : 162-175
Keywords : Antipsoriatic drugs; Drug design; Molecular docking; Molecular Simulation; retinoic acid receptor; Tazarotene;
Abstract
Design of novel antipsoriatic drugs based on the medicinal compound Tazarotene is the main purpose of the present study. Firstly, the molecular structures of Tazarotene and its derivatives (F, Cl, CH3, OCH3, COOH, OH, NH2 and CF3) were optimized using density functional theory (DFT) at B3LYP/6-311++G (d, p) computational method. Then, the optimized molecules were docked into the active site of the retinoic acid receptors. The molecular docking analyses revealed that, the Tazarotene derivatives with COOH, CF3 and OCH3 substituents can make strongest complexes with RAR-alpha, RAR-beta and RAR-gamma, respectively. Based on the physicochemical properties calculations, it was cleared that the CF3 derivative of Tazarotene has better properties (receptor-ligand interaction efficiency, lipophilicity and skin permeation) compared with that of the Tazarotene.
Other Latest Articles
- Evaluation of reaction of aza Michael catalyzed by raw red clay of Adrar-Algeria zone, under solvent-free conditions, and at room temperature
- An overview on antitubercular activity profile of fluoroquinolone derivatives and their molecular hybridization
- Evaluation of the phytoremediation performance of Hammada scoparia and Halocnemum Strobilaceum for Cu, Fe, Zn and Cr accumulation from the industrial area in Benghazi, Libya
- Isolation of olean-12(13), 15 (16)-diene, olean-12(13), 15(16)-dien-3β-oland olean-15(16)-en-11α-ol from the pet-benzene extract of Psidiumguajava and their biocidal activity
- Study of heterocyclic-fused pyridazinone analogues having phosphodiestrase-IV inhibitor activities as anti-inflammatory agents
Last modified: 2020-02-24 07:02:46